NCT03206151View on ClinicalTrials.gov

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

520

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

CMAB009

for injection only

DRUG

Irinotecan

for injection only

DRUG

Folinic acid

for injection only

DRUG

5-fluorouracil

for injection only

Trial Locations (2)

100021

Cancer hospital Chinese academy of medical sciences, Beijing

300000

Tianjing medical university cancer institute and hospital, Tianjin

All Listed Sponsors

lead

Taizhou Mabtech Pharmaceutical Co.,Ltd

INDUSTRY

NCT03206151 - CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter